and chronic obstructive pulmonary disease in different age populations. More than 1,000,000 patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Regeneron and ...

Sanofi SNY reported third-quarter 2024 adjusted earnings of $1.57 per American depositary share, which beat the Zacks ...

Sales of Dupixent rose by 24 per cent to about 3.5 billion ... from regulators in Europe and the US to treat the lung ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.

Multinational pharmaceutical and medical equipment companies will bring a variety of innovative medical solutions that ...

As people live longer than ever before, the incidence of aging-related, chronic diseases is on the rise, severely impacting ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to support US regulatory resubmission by year-end; if ...

Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI: Paris Saturday, October 26, 2024, 12:00 Hrs [IST] Positive data from the ...

and chronic obstructive pulmonary disease in different age populations. More than 1,000,000 patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Sanofi and ...

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved ...

and chronic obstructive pulmonary disease in different age populations. More than 1,000,000 patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Regeneron and ...